Brought to you by:
New long-term data of paclitaxel devices continue to show no increased mortality compared to non-drug coated devices
New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions (May 19–22) in Atlanta. The analysis…
Tissue samples show paclitaxel effect in minority of CLTI patients receiving DCB angioplasty, study finds
Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent on DCB type, nor the dose level of the drug administered, and was not associated with…
New sirolimus data provide encouragement despite ‘potentially disappointing’ efficacy results
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access for dialysis. These findings were delivered by Tjun Tang, MD—who also highlighted “excellent” technical and clinical…
Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT AV DCBs
Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential for pouch damage resulting in a loss of sterility. This is according to a news alert…
‘Proceed cautiously in use of DCBs in CLTI patients with advanced WIfI stage’
The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial disease (PAD). The latest contribution from Konstantinos Katsanos, MD, and colleagues raises questions about potential increased…
PCBs: Panel of vascular surgeons review latest findings on paclitaxel-coated balloons
A recent meta-analysis by Konstantinos Katsanos, MD, of Patras University Hospital, Rion, Greece, and colleagues—“Risk of major amputation following application of paclitaxel-coated balloons [PCBs] in the lower-limb arteries: A systematic review and meta-analysis of randomized controlled trials [RCTs],” published in…
VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism
A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional radiologist Konstantinos Katsanos, MD, that reported a heightened risk of major amputation after use of paclitaxel-coated balloons…
VAM: Industry-sponsored symposia
Industry-sponsored symposia at the Vascular Annual Meeting (VAM) will be presented Wednesday and Thursday evenings and at three breakfast sessions taking place Thursday morning. Industry-supported evening Satellite Symposia will be held from 6:30 to 8 p.m. Wednesday and Thursday. Wednesday’s…
The top 10 most popular Vascular Specialist stories in July
The digital version of our July 2021 print issue, an argument in favor of a multidisciplinary approach to limb salvage and look back at the career of a former Society for Vascular Surgery (SVS) president were among the most-read stories…
ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices
Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky, MD, an interventional cardiologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, reported this conclusion…